Evelina Vågesjö
PhD in physiology, MBA focus Finance and MnA. Co-founder and CEO Ilya Pharma AB Developed methods to steer immune cell functions and delineated a new mechanism of action during in tissue regeneration. Have managed the project from initial idea, a patent portfolio of 4 families with 25+ granted patents, proof of principle of two assets, ILP100-Topical and ILP100-Oral, clinical proof of concept of the lead asset, development of the team and company, to date raised 350 mSEK from multiple type of investors, local, European and US-based, lead acquisitions in the form of vertical integration in supply chain for ATMPs. Board position in Lytix Biopharma AS, clinical stage IO company developing lytic molecules for cancer treatment, with fully owned and partnered assets (LYTIX, traded on Euronext Oslo).